Positions

Overview

  • Dr. Luckhardt completed her medical training in May 2000 from the Louisiana State University Health Sciences Center in Shreveport, Louisiana, where she graduated Alpha Omega Alpha. She completed her Internal Medicine training at the University of Iowa Hospitals and Clinics in 2003. She was Chief Resident of Internal Medicine at the University of Iowa from 2003-2004. She then completed her Pulmonary and Critical Care Training at the University of Michigan. She was appointed as faculty there from 2007 until 2009 when she joined the faculty at UAB. Dr. Luckhardt has also completed a Masters program at the University of Michigan in 2009 in Clinical Research Design and Biostatistics. She has served on the American Thoracic Society Training committee, and on the University of Michigan's Pulmonary Fellow's Education committee.

    Dr. Luckhardt has particular interests in evaluating and treating patients with interstitial lung disease. She is working to build collaborations with Rheumatology and Cardiology to treat patients with interstitial lung disease and in particular patients with connective tissue disease-associated ILD. Dr. Luckhardt is also the Medical Director of the inpatient Pulmonary services and the Specialty Care Unit and has interest in the management of patients with advanced lung disease and chronic respiratory failure.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis data from the idiopathic pulmonary fibrosis prospective outcomes registryAnnals of the American Thoracic Society.  17:699-705. 2020
    2020 Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohortBMC Pulmonary Medicine.  20. 2020
    2020 The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosisRespiratory Medicine.  161. 2020
    2020 Updated evaluation of the safety, efficacy and tolerability of pirfenidone in the treatment of idiopathic pulmonary fibrosis 2020
    2019 Preoperative Evaluation of Patients With Interstitial Lung DiseaseChest.  156:826-833. 2019
    2019 Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patientsPLoS ONE.  14. 2019
    2019 Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapiesAmerican Journal of Respiratory and Critical Care Medicine.  200:133-139. 2019
    2019 Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  200:199-208. 2019
    2017 Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung diseaseAging Cell.  16:1114-1124. 2017
    2017 Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort studyEuropean Respiratory Journal.  50. 2017
    2017 Measures of frailty in chronic lung diseasesAnnals of the American Thoracic Society.  14:1266-1267. 2017
    2017 Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-β 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugsJCI insight.  2. 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.JCI insight.  2:e91377. 2017
    2017 What is in a pattern? that which we call idiopathic pulmonary fibrosis by any other pattern would behave alike!American Journal of Respiratory and Critical Care Medicine.  195:10-12. 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survivalRespiratory Medicine.  115:33-38. 2016
    2016 Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where to Now?Drugs.  76:291-300. 2016
    2015 Systemic sclerosis-associated fibrosis: An accelerated aging phenotype?Current Opinion in Rheumatology.  27:571-576. 2015
    2014 Therapeutic targeting of Src kinase in myofibroblast differentiation and pulmonary fibrosisJournal of Pharmacology and Experimental Therapeutics.  351:87-95. 2014
    2014 NADPH oxidases in lung health and diseaseAntioxidants and Redox Signaling.  20:2838-2853. 2014
    2012 Neuronal Wiskott-Aldrich syndrome protein (N-WASP) is critical for formation of α-smooth muscle action filaments during myofibroblast differentiation 2012
    2012 Update in diffuse parenchymal lung disease 2011American Journal of Respiratory and Critical Care Medicine.  186:24-29. 2012
    2011 TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis 2011
    2011 New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosisDrugs.  71:981-1001. 2011
    2010 Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repairAmerican Journal of Respiratory and Critical Care Medicine.  182:1030-1037. 2010
    2010 Latent herpesvirus infection augments experimental pulmonary fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  181:465-477. 2010
    2009 NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injuryNature Medicine.  15:1077-1081. 2009

    Chapter

    Year Title Altmetric
    2010 Addictive Disorders in the Intensive Care Unit.  167-179. 2010

    Research Overview

  • To complement her clinical interest in interstitial lung disease, Dr. Luckhardt has undertaken basic and translational investigations into the pathogenesis of idiopathic pulmonary fibrosis. She is principal investigator and co-investigator on multiple industry sponsored clinical trials in IPF and CTD-ILD. She also has a grant from the Pulmonary Fibrosis Foundation to study frailty as an outcome measure for IPF.
  • Principal Investigator On

  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2024
  • UAB Interstitial Lung Disease Program  awarded by Pulmonary Fibrosis Foundation 2019 - 2023
  • Private Grant  awarded by FIBROGEN, INC. 2020 - 2023
  • Private Grant  awarded by PRIME EDUCATION LLC 2020 - 2023
  • Private Grant  awarded by GALAPAGOS NV. 2020 - 2023
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University 2019 - 2021
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2018 - 2020
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh 2017 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh 2018 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University 2018 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2019
  • Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis  awarded by Pulmonary Fibrosis Foundation 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2015
  • Private Grant  awarded by MedImmune 2014 - 2015
  • TLR9 Activation and Fibrotic Responses in Alveolar Epithelial Cells  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2013
  • Investigator On

  • Private Grant  awarded by GENKYOTEX SA 2020 - 2025
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Core C: Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by RESPIVANT SCIENCES, GMBH 2019 - 2022
  • Private Grant  awarded by CHIMERIX, INC. 2020 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD 2019 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by MALLINCKRODT ARD, INC 2018 - 2021
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018 - 2021
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2018 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2019
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2015 - 2018
  • Rituximab Therapy in Patients with IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2018
  • PAI-1 and Aging-Related Susceptibility to Lung Fibrosos  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro)  awarded by Duke University 2014 - 2018
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by FIBROGEN, INC. 2013 - 2018
  • Private Grant  awarded by Genentech 2013 - 2018
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by FIBROGEN, INC. 2010 - 2017
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2017
  • Private Grant  awarded by INTERMUNE, INC. 2008 - 2015
  • Private Grant  awarded by INTERMUNE, INC. 2014 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2014
  • Private Grant  awarded by MedImmune 2013 - 2014
  • Private Grant  awarded by VERILOGUE, INC. 2013
  • Private Grant  awarded by Gilead Sciences 2013
  • Teaching Overview

  • Dr. Luckhardt has served as a mentor for several fellows pursuing translational and outcomes based projects in interstitial lung disease.
  • Education And Training

  • Doctor of Medicine, Louisiana State University System : Shreveport 2000
  • University of Iowa Hospitals and Clinics, Internship 2001
  • University of Iowa Hospitals and Clinics, Residency 2003
  • University of Michigan Hospitals & Health Centers, Postdoctoral Fellowship 2007
  • Full Name

  • Tracy Luckhardt